Eirion describes ET-02 as designed to restore normal activity to hair follicle stem cells that have become dysfunctional or inactive with age, rather than working through the androgen pathway that finasteride and dutasteride, and topical androgen-receptor drugs like clascoterone, all work through. The company's own materials and independent academic coverage are consistent on this point: Eirion states directly that ET-02 does not target hormonal pathways and therefore does not expect it to produce the sexual side effects associated with androgen-suppressing treatments, and a 2026 academic review of emerging AGA pharmacotherapies places ET-02 in a distinct category, "metabolic and follicular activators," alongside PP405, separate from the androgen-receptor antagonists and degraders category that includes clascoterone and GT20029.

The trial itself did not measure androgen-pathway endpoints; its efficacy assessments instead focused on hair count and hair width. Those outcomes are consistent with the company's proposed follicular mechanism, but they don't independently establish how ET-02 produces its effects, since ET-02's precise molecular target hasn't been publicly disclosed.

Before human trials, Eirion tested 5% topical ET-02 on human scalp tissue grafts taken from men with intermediate-stage androgenetic alopecia, transplanted onto a mouse model, an established method for testing topical actives on human follicles without a full human trial. The company's own press materials give inconsistent graft counts across two separate announcements, 90 grafts in the July 2024 trial-initiation release and 60 grafts in the January 2025 results release; it isn't clear from public materials whether these describe the same study reported differently or two separate preclinical rounds. Either way, this is company-reported preclinical data, not an independently published, peer-reviewed study.

Within that caveat, the graft studies are the basis for Eirion's claim that ET-02 outperformed minoxidil in a separate historical graft study using the same model, a comparison covered in more detail below because it carries the same caveat forward into the human trial data.

The first-in-human trial was double-blind, placebo-controlled, and dose-ranging: 24 men across three US sites, once-daily application for 28 days, split into cohorts receiving vehicle, 1.25% ET-02, or 5% ET-02. In Eirion's own analysis, the 1.25% dose group showed no meaningful difference from vehicle and was pooled into the placebo group for comparison, meaning the reported results reflect the 5% dose specifically, not ET-02 at any concentration.

That last point is the one worth sitting with. Comparing a 24-person trial against a different 180-person trial run at a different time, in a different patient population, with different assessment protocols, is not the same claim as testing ET-02 against minoxidil head-to-head in the same study. The sixfold-versus-placebo figure is a direct, within-trial comparison and stands on its own. The minoxidil comparison is an across-trial comparison, which is a meaningfully weaker form of evidence even when the underlying numbers are accurately reported.

Eirion's CEO outlined Phase 2 plans in a January 2025 interview: a planned trial of roughly 150 participants with treatment extending to six months, with possible inclusion of women to assess efficacy across sexes, since the Phase 1 trial enrolled men only. As of the most recent public reporting available, Phase 2 has been described in this level of detail but a confirmed enrolment or start date has not been publicly announced.

Two other threads are worth knowing about without over-weighting them yet. Eirion has stated it believes the same mechanism could apply to hair greying by acting on melanocyte stem cells, and has said it plans to explore this in future work; nothing has been tested in this application yet. Separately, the company has mentioned preclinical development of an oral version of ET-02, with no further detail publicly available. Both are stated intentions rather than results.

Every specific figure in this article, the graft counts, the sixfold hair count increase, the hair width improvement, the minoxidil comparison, comes from Eirion's own press releases and trade press coverage of those releases. None of it has been published in a peer-reviewed journal at the time of writing, and none of it has been independently replicated by researchers outside the company. That doesn't make the figures false; press-released trial data from a company running its own trial is a common and normal stage for a drug at this point in development. It does mean the number to hold onto is 24, the size of the trial the topline claims are drawn from, and that a 24-person, 28-day trial with hair growth as a secondary endpoint is early-stage evidence, not a settled result.

The mechanism itself is the more interesting part of this story regardless of how the efficacy numbers eventually hold up. A non-hormonal approach aimed at follicle stem cell dysfunction, if it works, would sidestep the side-effect profile that puts a meaningful number of people off finasteride and dutasteride entirely. Whether it does work is a question the planned six-month, 150-person Phase 2 trial is positioned to start answering, not one the current data can settle.

This article is provided for educational purposes and does not constitute medical or investment advice. ET-02 is an investigational compound not approved for any use by the FDA, MHRA, or any other regulatory body, and its safety and efficacy have not been independently established. AmpleLab products are unrelated to ET-02 and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.